Cornea A Phase 3, multi-center, randomized, parallel, double masked, placebo-controlled clinical study to assess the safety and efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2) […]
Read More… from Active Clinical Trials at the Vision Institute